help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Halleux, C. M.
Right arrow Articles by Brichard, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halleux, C. M.
Right arrow Articles by Brichard, S. M.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 11 4097-4105
Copyright © 1999 by The Endocrine Society


Original Studies

Hormonal Control of Plasminogen Activator Inhibitor-1 Gene Expression and Production in Human Adipose Tissue: Stimulation by Glucocorticoids and Inhibition by Catecholamines1

C. M. Halleux, P. J. Declerck, S. L. Tran, R. Detry and S. M. Brichard2

Endocrinology and Metabolism Unit, Surgery Unit (R.D.), University of Louvain, Faculty of Medicine, UCL 5530, B-1200 Brussels; and Pharmaceutical Biology and Phytopharmacology Unit, University of Leuven, Faculty of Pharmaceutical Sciences, KUL (P.J.D.), Van Evenstraat 4, B-3000 Leuven, Belgium

Address all correspondence and requests for reprints to: S. M. Brichard, Unité d’Endocrinologie et Métabolisme, UCL 5530 avenue Hippocrate 55, B-1200 Brussels, Belgium.

Plasma levels of type 1 plasminogen activator inhibitor (PAI-1), a risk factor for cardiovascular disease, are elevated in obese subjects, especially those with omental fat accumulation. We investigated the hormonal control of PAI-1 gene expression and secretion in cultured human adipose tissue. We more particularly focused on the effects of glucocorticoids, insulin, cAMP, and catecholamines in explants from the omental region. The addition of dexamethasone to the culture medium increased PAI-1 secretion in a time-dependent manner for up to 24 h. The stimulation by the glucocorticoid was preceded by a 2-fold rise in PAI-1 messenger ribonucleic acid levels between 4–8 h of culture. The effectiveness of the glucocorticoid was concentration dependent, with a half-maximal effect within a physiological range. This stimulation was also observed in sc fat, but dexamethasone-stimulated as well as basal PAI-1 secretion rates were always higher in omental fat. Unlike dexamethasone, 24-h insulin did not modify PAI-1 secretion while accelerating glucose consumption. In contrast, 24-h cAMP inhibited PAI-1 gene expression and protein production under basal conditions and in the presence of dexamethasone. This inhibition was already detectable after 1 h and was maximal after 4 h at the level of gene expression. It occurred in both omental and sc adipose tissues. Importantly, epinephrine dose dependently inhibited PAI-1 parameters, an effect that was reproduced by isoproterenol. Dexamethasone- and cAMP-induced changes in PAI-1 messenger ribonucleic acid abundance were similar in explants and isolated fat cells. In isolated stromal-vascular cells, only dexamethasone was effective. In conclusion, we provide evidence for a reciprocal regulation of PAI-1 by dexamethasone (positive effector) and cAMP/catecholamines (negative effectors) in cultured human adipose tissue. The stimulation by glucocorticoids could contribute to enhanced production of PAI-1 by adipose tissue and high plasma levels of PAI-1 associated with central obesity and thereby be a link between this disorder and cardiovascular disease. Impaired inhibition by catecholamines could also contribute, as in vivo adipose tissue responses to these hormones are usually blunted in obese individuals.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. Van Zaane, E. Nur, A. Squizzato, O. M. Dekkers, M. B. Twickler, E. Fliers, V. E. A. Gerdes, H. R. Buller, and D. P. M. Brandjes
Hypercoagulable State in Cushing's Syndrome: A Systematic Review
J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2743 - 2750.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Maury, L. Noel, R. Detry, and S. M. Brichard
In Vitro Hyperresponsiveness to Tumor Necrosis Factor-{alpha} Contributes to Adipokine Dysregulation in Omental Adipocytes of Obese Subjects
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1393 - 1400.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
F. Wang and Q. Tong
Transcription factor PU.1 is expressed in white adipose and inhibits adipocyte differentiation
Am J Physiol Cell Physiol, July 1, 2008; 295(1): C213 - C220.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. French, L. H. Hamilton, L. A. Mattano Jr, H. N. Sather, M. Devidas, J. B. Nachman, and M. V. Relling
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group
Blood, May 1, 2008; 111(9): 4496 - 4499.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E. Maury, K. Ehala-Aleksejev, Y. Guiot, R. Detry, A. Vandenhooft, and S. M. Brichard
Adipokines oversecreted by omental adipose tissue in human obesity
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E656 - E665.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
P. Darmon, F. Dadoun, S. Boullu-Ciocca, M. Grino, M.-C. Alessi, and A. Dutour
Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E995 - E1002.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M.-C. Alessi and I. Juhan-Vague
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2200 - 2207.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
I. Mertens, R. V Considine, M. Van der Planken, and L. F Van Gaal
Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin?
Eur. J. Endocrinol., September 1, 2006; 155(3): 477 - 484.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Fujita, M. Kang, M. Eren, L. A. Gleaves, D. E. Vaughan, and T. Kume
Foxc2 Is a Common Mediator of Insulin and Transforming Growth Factor {beta} Signaling to Regulate Plasminogen Activator Inhibitor Type I Gene Expression
Circ. Res., March 17, 2006; 98(5): 626 - 634.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Feinbloom and K. A. Bauer
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2043 - 2053.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Tchkonia, Y. D. Tchoukalova, N. Giorgadze, T. Pirtskhalava, I. Karagiannides, R. A. Forse, A. Koo, M. Stevenson, D. Chinnappan, A. Cartwright, et al.
Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E267 - E277.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. P. Girod and D. J. Brotman
Does altered glucocorticoid homeostasis increase cardiovascular risk?
Cardiovasc Res, November 1, 2004; 64(2): 217 - 226.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Duclos, C. Gouarne, C. Martin, C. Rocher, P. Mormede, and T. Letellier
Effects of corticosterone on muscle mitochondria identifying different sensitivity to glucocorticoids in Lewis and Fischer rats
Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E159 - E167.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Sawathiparnich, S. Kumar, D. E. Vaughan, and N. J. Brown
Spironolactone Abolishes the Relationship between Aldosterone and Plasminogen Activator Inhibitor-1 in Humans
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 448 - 452.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. Sarkar, S.-W. Tsai, T. T. Nguyen, M. Plevyak, J. F. Padbury, and L. P. Rubin
Inhibition of placental 11beta -hydroxysteroid dehydrogenase type 2 by catecholamines via alpha -adrenergic signaling
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R1966 - R1974.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Skurk, Y.-M. Lee, and H. Hauner
Angiotensin II and Its Metabolites Stimulate PAI-1 Protein Release From Human Adipocytes in Primary Culture
Hypertension, May 1, 2001; 37(5): 1336 - 1340.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Chadarevian, E. Bruckert, L. Leenhardt, P. Giral, A. Ankri, and G. Turpin
Components of the Fibrinolytic System Are Differently Altered in Moderate and Severe Hypothyroidism
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 732 - 737.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society